Somatostatin versus octreotide in the treatment of patients with gastrointestinal and pancreatic fistulas

Abstract

Data suggest that pharmacotherapy reduces the costs involved in fistula management (by reducing hospitalization) and also offers increased spontaneous closure rate. Further prospective studies focusing on the above parameters are needed to demonstrate the clinicoeconomic benefits.